IQT0 Stock Chart & Stats
€2.50
€0.00(0.00%)
At close: 4:00 PM EDT
€2.50
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€2.50 - €2.50
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€197.70M
Enterprise Value€195.36M
Total Cash (Recent Filing)€159.02M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-8.83
Next Earnings
Nov 16, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding139,535,900
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.17
Price to Sales (P/S)0.00
P/FCF Ratio-7.25
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.98Price Target Upside99.08% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.39
Revenue Forecast (FY)€254.60K
Bulls Say, Bears Say
Bulls Say
Debt-Free Balance SheetEffectively zero debt limits interest expense and reduces solvency pressure while the company funds clinical development. This gives management greater flexibility to allocate capital toward IKT-001 and other research priorities, although it does not eliminate the need for future financing.
Phase 3 ProgressEnrollment across a broad international Phase 3 network marks meaningful clinical advancement and moves IKT-001 closer to a regulatory decision. Progress at this stage can improve development visibility and create a clearer path toward potential commercial revenue if efficacy and safety are demonstrated.
Orphan Drug DesignationOrphan Drug Designation strengthens the development economics of IKT-001 by providing regulatory incentives and the possibility of market exclusivity if approved. These benefits can lower development friction and improve the candidate’s potential competitive position in an underserved indication.
Bears Say
No Commercial RevenueThe absence of meaningful revenue confirms that the company remains dependent on clinical execution before establishing a commercial business. Until a therapy is approved and launched, operating costs are unlikely to be supported by product sales, leaving financial performance highly sensitive to development outcomes.
Widening LossesWidening losses indicate that advancing the pipeline is consuming more capital without corresponding revenue growth. Persistent deterioration in earnings increases the amount of funding required before commercialization and reduces near-term earnings visibility, even if the lead program continues progressing clinically.
Increasing Cash BurnHigher operating and free cash burn increases the company’s runway requirements and makes continued access to external capital strategically important. The recurring cash outflow can constrain investment choices and expose shareholders to financing risk before any prospective product revenue begins.
Inhibikase Therapeutics News
IQT0 FAQ
What was Inhibikase Therapeutics’s price range in the past 12 months?
Inhibikase Therapeutics lowest stock price was €2.50 and its highest was €2.50 in the past 12 months.
What is Inhibikase Therapeutics’s market cap?
Inhibikase Therapeutics’s market cap is €197.70M.
When is Inhibikase Therapeutics’s upcoming earnings report date?
Inhibikase Therapeutics’s upcoming earnings report date is Nov 16, 2026 which is in 21 days.
How were Inhibikase Therapeutics’s earnings last quarter?
Inhibikase Therapeutics released its earnings results on Aug 11, 2026. The company reported -€0.098 earnings per share for the quarter, missing the consensus estimate of -€0.096 by -€0.002.
Is Inhibikase Therapeutics overvalued?
According to Wall Street analysts Inhibikase Therapeutics’s price is currently Undervalued.
Does Inhibikase Therapeutics pay dividends?
Inhibikase Therapeutics does not currently pay dividends.
What is Inhibikase Therapeutics’s EPS estimate?
Inhibikase Therapeutics’s EPS estimate is -0.1.
How many shares outstanding does Inhibikase Therapeutics have?
Inhibikase Therapeutics has 139,535,900 shares outstanding.
What happened to Inhibikase Therapeutics’s price movement after its last earnings report?
Inhibikase Therapeutics reported an EPS of -€0.098 in its last earnings report, missing expectations of -€0.096. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Inhibikase Therapeutics?
Currently, no hedge funds are holding shares in DE:IQT0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Inhibikase Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€4.98 (99.08% Upside)
€4.98 (99.08% Upside)
Blogger Sentiment
Bullish
DE:IQT0 Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
3.92%
12-Months-Change
Fundamentals
Return on Equity
-42.80%
Trailing 12-Months
Asset Growth
84.11%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Inhibikase Therapeutics
Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics to modify the course of cardiopulmonary diseases, with a primary focus on pulmonary arterial hypertension (PAH), a progressive, life-threatening disease characterized by pulmonary vascular remodeling and elevated pulmonary vascular resistance. It offers IKT-001, a novel oral prodrug of imatinib mesylate designed for the treatment of pulmonary arterial hypertension (PAH) was designed to improve areas of the molecule that might play a role in the gastrointestinal side effects associated with imatinib, while maintaining systemic exposure and efficacy through oral administration. The company has completed non-human primate safety studies and a bioequivalence clinical study in healthy volunteers, establishing dose equivalence with imatinib. IKT-001 is currently being evaluated in a global, adaptive Phase 3 clinical trial (IMPROVE-PAH), with endpoints including pulmonary vascular resistance and 6-minute walk distance. Inhibikase Therapeutics, Inc. entered into a collaborative research and development agreement with Sphaera Pharma Pte. Ltd., which was subsequently assigned to Pivot Holding LLC, for prodrug technology development and maintains an exclusive license for IKT-001. The company was founded in 2008 and is headquartered in Wilmington, Delaware.
IQT0 Stock 12 Month Forecast
Average Price Target
€4.98
▲(99.08% Upside)
Technical Analysis
Atossa Therapeutics
―
Anixa Biosciences
―
Spero Therapeutics
―
Surrozen
―
TScan Therapeutics
―